- Product Details
- Instructions For Use
- Validation Data
- Additional Information
- References, Applications
|Method:||Sandwich ELISA, HRP/TMB, 12x8-well strips|
|Sample type:||Serum, plasma (EDTA, heparin), urine protocol available|
|Standard range:||0-240 pmol/l (6 serum based standards)|
|Standard points:||0/15/30/60/120/240 pmol/l|
|Control:||1 serum based control|
|Sample size:||20 µl / well|
|Incubation time:||Overnight / 1 h / 30 min|
|Unit conversion:||1 pg/ml = 0.044 pmol/l (MW: 22.5 kDa)|
LOD: 3.2 pmol/l (0 pmol/l + 3 SD); LLOQ: < 7.5 pmol/l
Intra-assay (n=8) ≤ 7%, Inter-assay (n=6) ≤ 10%
The mean recovery of recombinant Sclerostin in human serum samples (n=6) is 94%.
The mean dilution linearity of endogenous Sclerostin in human serum samples (n=4) is 110% for dilution factors 1+1, 1+3, 1+7.
The mean dilution linearity for recombinant Sclerostin in human serum samples (n=3) is 98% for dilution factors 1+1, 1+3.
The assay does not detect Noggin.
The assay does not detect Wise (SOSTDC1).
Species cross reactivity:
Rat, mouse: The assay does not detect rat or mouse Sclerostin.
Primates: The sequence homology of human Sclerostin to various primate species is >95%. It is likely that the assay can be used for these species. Internal validations have not been carried out. However, data from other laboratories show positive results.
Serum values from apparently healthy individuals:
Median (serum, n=411): 24.14. pmol/l.
It is recommended to establish the normal range for each laboratory.
Principle of the assay:
Manual ELISAs - easily adaptable for automation!
INSTRUCTIONS FOR USE
Click here for IFU.
Click here for assay validation data (S/R, dilution linearity, precision, ...).
Canonical Wnt-signalling plays an important role in the regulation of bone homeostasis by promoting the development of osteoblasts. Negative regulators of the Wnt pathway are important new therapeutic targets for the treatment of diseases with enhanced bone resorption. One of these molecules is Sclerostin, a 22.5 kD secreted glycoprotein, which acts by binding to the Wnt-coreceptor LRP5 thus preventing the binding of Wnt molecules.
Sclerostin is nearly exclusively produced in osteocytes. Therefore it is considered a clinical marker which provides highest bone specificity.
Click here for MSDS
Click here for PRODUCT LEAFLET
Click here for SCLEROSTIN in NEPHROLOGY
Click here for BIOMARKERS in CLINICAL NEPHROLOGY
Click here for BIOMARKERS in CLINICAL OSTEOLOGY
Click here for reference list.